Skip to main content
AdvisorShares Psychedelics ETF—— (—)Compass Pathways—— (—)Definium Therapeutics—— (—)GH Research—— (—)Helus Pharma—— (—)MIRA Pharmaceuticals—— (—)Neuphoria Therapeutics—— (—)Eli Lilly—— (—)Johnson & Johnson—— (—)AbbVie—— (—)Otsuka Pharmaceutical—— (—)Numinus Wellness—— (—)Optimi Health—— (—)PharmAla Biotech—— (—)Enveric Biosciences—— (—)Incannex Healthcare—— (—)Aurora Cannabis—— (—)Cronos Group—— (—)SNDL—— (—)Bright Minds Biosciences—— (—)PharmaTher Holdings—— (—)IM Cannabis—— (—)MariMed—— (—)Vireo Growth—— (—)
Loading prices
Back to the NewsWire

Morningstar

Published November 17, 2026

BetterLife Pharma Announces New Preclinical Research Highlighting Neuroplasticity ... - Morningstar

Read the full story at Morningstar

"The ability to engage molecular pathways associated with neuroplasticity, without the hallucinogenic effects seen with classical psychedelics in.

Surfaced by 4 Google Alerts

  • Psychedelics
  • LSD
  • Psychedelic press release
  • Psychedelic biotech